By Digifin Pty Ltd · About this coverage
Key Points
- 1H FY27 guidance: operating revenue about NZ$1.24b and NPAT about NZ$280m
- FY27 revenue guidance now about NZ$2.47b-NZ$2.57b, from about NZ$2.45b-NZ$2.57b in May
- FY27 NPAT guidance now about NZ$525m-NZ$565m, from about NZ$500m-NZ$550m in May
- NPAT guidance incorporates $23m in US IEEPA tariff refunds; the release states no currency
- 1H growth of about 14% in reported operating revenue and about 24% in NPAT (excluding US tariff refunds)
About Fisher & Paykel Healthcare (ASX:FPH)
Fisher & Paykel Healthcare Corporation Limited is a medical device manufacturer headquartered in Auckland, New Zealand, with its shares listed on both the NZX and the ASX. It designs and makes humidified respiratory support systems, including nasal high flow and invasive and non-invasive ventilation products, together with masks and devices for treating obstructive sleep apnea and humidification systems used in surgery. It sells to hospitals and homecare providers internationally and reports in New Zealand dollars.
Fisher & Paykel Healthcare (ASX:FPH) provided guidance for the first half of its 2027 financial year, which ends 30 September 2026, and updated its guidance for the full 2027 financial year. The company is New Zealand-domiciled and its guidance is expressed in New Zealand dollars, with assumptions struck at 31 July 2026 exchange rates of NZD:USD 0.59, NZD:EUR 0.51 and NZD:MXN 10.17. On those rates, and on guidance assumptions that include a continuation of the current trading environment, it expects first half operating revenue of approximately NZ$1.24 billion and net profit after tax of approximately NZ$280 million. The company said this would equate to approximately 14% growth in reported operating revenue and approximately 24% growth in net profit after tax (excluding the impact of US tariff refunds), compared with the first half of the 2026 financial year. Managing Director and Chief Executive Officer Lewis Gradon said the company had a strong start to the first half, particularly in its Hospital product group, as a result of continued strong demand for its latest range of hardware devices and ongoing change in clinical practice driving consumable sales, and that it was pleasing to see the progress being made with its continuous improvement activities and the impact on gross margin and other operating efficiencies.
For the full 2027 financial year, and at the same 31 July exchange rates, Fisher & Paykel Healthcare now expects operating revenue of approximately NZ$2.47 billion to NZ$2.57 billion and net profit after tax of approximately NZ$525 million to NZ$565 million. The guidance previously provided in May was for operating revenue of approximately NZ$2.45 billion to NZ$2.57 billion and net profit after tax of approximately NZ$500 million to NZ$550 million. The company said the first half and full year net profit after tax guidance incorporates $23 million in US IEEPA tariff refunds, a figure the release states without a currency prefix, and that the full year outlook continues to anticipate an overall improvement in gross margin and also assumes current global tariff rates, policies and applications for the duration of this financial year. Fisher & Paykel Healthcare also confirmed its 2026 Annual Shareholders' Meeting is scheduled for 2:00pm NZST, 12:00pm AEST, on Tuesday 25 August 2026.
Source: Fisher & Paykel Healthcare Corporation Limited (ASX:FPH), 21 August 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.